New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia

Journal of Clinical Oncology

Volumn 27, Issue 31, 2009, Pages 5219-5226

  Tiu, Ramon V ^a   Gondek, Lukasz P ^a   O'Keefe, Christine L ^a   Huh, Jungwon ^a   Sekeres, Mikkael A ^a   Elson, Paul ^a   McDevitt, Michael A ^a   Wang, Xiao Fei ^a   Levis, Mark J ^a   Karp, Judith E ^a   Advani, Anjali S ^a   Maciejewski, Jaroslaw P ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; 5 AZA 2' DEOXYCYTIDINE; ARSENIC; AZACITIDINE; CHLORMETHINE; CLOFARABINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLAVOPIRIDOL; FLT3 LIGAND; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; HYDROXYUREA; IDARUBICIN; LENALIDOMIDE; MITOXANTRONE; NUCLEOPHOSMIN; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; NUCLEAR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; DOSE RESPONSE; DRUG MEGADOSE; EVENT FREE SURVIVAL; HUMAN; KARYOTYPE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; METASTASIS; MICROARRAY ANALYSIS; PRIMARY TUMOR; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; UNIPARENTAL DISOMY; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; KARYOTYPING; METHODOLOGY; MIDDLE AGED; MORTALITY; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; DISEASE-FREE SURVIVAL; FMS-LIKE TYROSINE KINASE 3; HUMANS; KAPLAN-MEIERS ESTIMATE; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 70449715477     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.21.9840     Document Type: Article

References (49)

1. Schiffer CA, Lee EJ, Tomiyasu T, et al: Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 73:263-270, 1989
2. Slovak ML, Kopecky KJ, Cassileth PA, et al: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96:4075-4083, 2000
3. Grimwade D, Walker H, Harrison G, et al: The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98:1312-1320, 2001
4. Byrd JC, Mrozek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325-4336, 2002
5. Smith SM, Le Beau MM, Huo D, et al: Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series. Blood 102:43-52, 2003
6. Caligiuri MA, Strout MP, Lawrence D, et al: Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res 58:55-59, 1998
7. Thiede C, Steudel C, Mohr B, et al: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326-4335, 2002
8. Döhner K, Schlenk RF, Habdank M, et al: Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood 106:3740-3746, 2005
9. Schnittger S, Schoch C, Kern W, et al: Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 106:3733-3739, 2005
10. Bacher U, Haferlach T, Kern W, et al: A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica 92:744-752, 2007
11. Mead AJ, Linch DC, Hills RK, et al: FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 110: 1262-1270, 2007
12. Whitman SP, Ruppert AS, Marcucci G, et al: Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: A Cancer and Leukemia Group B study. Blood 109:5164-5167, 2007
13. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997
14. Haase D, Germing U, Schanz J, et al: New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood 110: 4385-4395, 2007
15. Gondek LP, Dunbar AJ, Szpurka H, et al: SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal abnormalities in MDS/MPD-U and MPD. PLoS ONE 2:e1225, 2007
16. Gondek LP, Haddad AS, O'Keefe CL, et al: Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low-risk myelodysplastic syndromes. Exp Hematol 35:1728-1738, 2007
17. Gondek LP, Tiu R, Haddad AS, et al: Single nucleotide polymorphism arrays complement metaphase cytogenetics in detection of new chromosomal lesions in MDS. Leukemia 21:2058-2061, 2007
18. Mohamedali A, Gaken J, Twine NA, et al: Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 110:3365-3373, 2007
19. Gondek LP, Tiu R, O'Keefe CL, et al: Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 111:1534-1542, 2008
20. Fitzgibbon J, Smith LL, Raghavan M, et al: Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res 65:9152-9154, 2005
21. Mohan SR, Elson P, Rodriguez CP, et al: Development of a prognostic scoring system for secondary acute myeloid leukemia (sAML) arising from myelodysplastic syndromes (MDS), myeloproliferative disorders (MPD), or therapy-related AML (t-AML). Blood 112:341, 2008 (abstr 921)
22. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the acute leukaemias: French-American-British (FAB) co-operative group. Br J Haematol 33:451-458, 1976
23. Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292-2302, 2002
24. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649, 2003
25. Shaffer LG, Tommerup N: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, Karger, 2005
26. Huh J, Gondek L, O'Keefe C, et al: Using combined high density SNP/CNV arrays as a clinical karyotyping tool in myeloid malignancies. Blood 112:535, 2008 (abstr 1504)
27. Tiu R, Gondek L, O'Keefe C, et al: Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes. Leukemia 21:1648-1657, 2007
28. Walker BA, Leone PE, Jenner MW, et al: Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms and genes important in the pathogenesis of multiple myeloma. Blood 108:1733-1743, 2006
29. Hidaka T, Nakahata S, Hatakeyama K, et al: Down-regulation of TCF8 is involved in the leukemogenesis of adult-T cell leukemia/lymphoma. Blood 112:383-393, 2008
30. Raghavan M, Lillington DM, Skoulakis S, et al: Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res 65:375-378, 2005
31. Kralovics R, Guan Y, Prchal JT: Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 30:229-236, 2002
32. Flotho C, Steinemann D, Mullighan CG, et al: Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11. Oncogene 26: 5816-5821, 2007
33. Griffiths M, Mason J, Rindl M, et al: Acquired isodisomy for chromosome 13 is common in AML, and associated with FLT3-itd mutations. Leukemia 19:2355-2358, 2005
34. Wouters BJ, Sanders MA, Lugthart S, et al: Segmental uniparental disomy as a recurrent mechanism for homozygous CEBPA mutations in acute myeloid leukemia. Leukemia 21:2382-2384, 2007
35. Gupta M, Raghavan M, Gale RE, et al: Novel regions of acquired uniparental disomy discovered in acute myeloid leukemia. Genes Chromosomes Cancer 47:729-739, 2008
36. Raghavan M, Smith LL, Lillington DM, et al: Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia. Blood 112:814-821, 2008
37. Serrano E, Carnicer MJ, Orantes V, et al: Uniparental disomy may be associated with microsatellite instability in acute myeloid leukemia (AML) with a normal karyotype. Leuk Lymphoma 49:1178-1183, 2008
38. Dunbar AJ, Gondek LP, O'Keefe CL, et al: 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 68:10349-10357, 2008
39. Grimwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 Trial. Blood 92:2322-2333, 1998
40. Paschka P, Marcucci G, Rupper AS, et al: Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8; 21): A Cancer and Leukemia Group B Study. J Clin Oncol 24:3904-3911, 2006
41. Fröhling S, Schlenk RF, Breitruck J, et al: Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. Blood 100:4372-4380, 2002
42. Moreno I, Martin G, Bolufer P, et al: Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica 88:19-24, 2003
43. Verhaak RG, Goudswaard CS, van Putten W, et al: Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): Association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 106:3747-3754, 2005
44. Schoch C, Kern W, Schnittger S, et al: The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica 89:1082-1090, 2004
45. Hug V, Keating M, McCredie K, et al: Clinical course and response to treatment of patients with acute myelogenous leukemia presenting with a high leukocyte count. Cancer 52:773-779, 1983
46. Rees JK, Gray RG, Swirsky D, et al: Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet 2:1236-1241, 1986
47. Dutcher JP, Schiffer CA, Wiernik PH: Hyperleukocytosis in adult acute nonlymphocytic leukemia: Impact on remission rate and duration, and survival. J Clin Oncol 5:1364-1372, 1987
48. Estey E, Smith TL, Keating MJ, et al: Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. Leukemia 3:257-263, 1989
49. Wheatley K, Burnett AK, Goldstone AH, et al: A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 107:69-79, 1999